YU5296A - Proteini protiv gojaznosti - Google Patents

Proteini protiv gojaznosti

Info

Publication number
YU5296A
YU5296A YU5296A YU5296A YU5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A YU 5296 A YU5296 A YU 5296A
Authority
YU
Yugoslavia
Prior art keywords
obesity
patients
agents
obesity proteins
proteins
Prior art date
Application number
YU5296A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Margaret Basinski
Richard Dimarchi
David Flora
John Hale
William Heath
James Hoffmann
Brigitte Schoner
Original Assignee
Eli Lilly And Company, Lilly Corporate Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Lilly Corporate Center filed Critical Eli Lilly And Company, Lilly Corporate Center
Publication of YU5296A publication Critical patent/YU5296A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
YU5296A 1995-01-31 1996-01-29 Proteini protiv gojaznosti YU5296A (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06
US45095P 1995-06-22 1995-06-22
US216195P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
YU5296A true YU5296A (sh) 1998-08-14

Family

ID=27484996

Family Applications (1)

Application Number Title Priority Date Filing Date
YU5296A YU5296A (sh) 1995-01-31 1996-01-29 Proteini protiv gojaznosti

Country Status (15)

Country Link
JP (1) JPH10513451A (no)
KR (1) KR19980701798A (no)
AR (1) AR002956A1 (no)
AU (1) AU703316B2 (no)
BR (1) BR9606999A (no)
CA (1) CA2211784A1 (no)
CO (1) CO4480035A1 (no)
CZ (1) CZ240497A3 (no)
FI (1) FI973162A (no)
NO (1) NO973515L (no)
NZ (1) NZ301589A (no)
PE (1) PE15197A1 (no)
PL (1) PL321702A1 (no)
TR (1) TR199600085A2 (no)
YU (1) YU5296A (no)

Also Published As

Publication number Publication date
CA2211784A1 (en) 1996-08-08
JPH10513451A (ja) 1998-12-22
KR19980701798A (ko) 1998-06-25
NO973515D0 (no) 1997-07-30
FI973162A (fi) 1997-09-30
NO973515L (no) 1997-09-29
FI973162A0 (fi) 1997-07-30
AU703316B2 (en) 1999-03-25
NZ301589A (en) 1999-02-25
TR199600085A2 (tr) 1996-08-21
AR002956A1 (es) 1998-05-27
BR9606999A (pt) 1997-10-28
PL321702A1 (en) 1997-12-22
PE15197A1 (es) 1997-05-22
CO4480035A1 (es) 1997-07-09
AU4705296A (en) 1996-08-21
CZ240497A3 (cs) 1998-01-14

Similar Documents

Publication Publication Date Title
WO2001096587A3 (en) Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DE60001271T2 (de) Hydroxymatairesinol in der krebs-prevention
ATE185149T1 (de) Immunogene verbindungen mit spezifischem anti- cytokin effekt, methode zur herstellung, pharmazeutische zusammensetzung und reaktionskit der diese enthält
DE69931907D1 (de) Zusammensetzungen aus hagebutten als anti-entzündliches natürliches arzneimittel zur erleichterung/verringerung von symptomen, die mit entzündungen und arthritis zusammenhängen
DE59811158D1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
MX9602689A (es) Usos terapeuticos humanos de los productos de proteina bpi.
ATE450622T1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
YU5296A (sh) Proteini protiv gojaznosti
WO2002055024A3 (en) Therapeutic modulation of the tumor inflammatory response
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
BR9708005A (pt) C3 convertase resistente à regulação para baixo
DE69804466T2 (de) Robinia pseudoacacia lektin und seine verwendungen
DE69712907T2 (de) Immunogene tlp-zusammensetzung
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
KR927003083A (ko) 인간 인터류킨 2 활성을 갖는 폴리펩티드 기재의 항종양제 조성물
TR199901385T2 (xx) Piperidin t�revleri.
WO2002000822A3 (fr) Nouveau polypeptide, sous-unite humaine 2 $g(b) 16.5 du facteur d'initiation necessaire a la synthese proteique, et polynucleotide codant ce polypeptide
Le et al. Influence of fractionation and time on local control of T1 and T2 glottic carcinoma